We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Bacterial Infection Test Differentiates Between MRSA and MSSA in 53 Minutes

By LabMedica International staff writers
Posted on 18 Jul 2023
Print article
Image: The Vivalytic MRSA/MSSA Rapid Test provides a quick diagnosis of methicillin resistance at the point of care (Photo courtesy of Randox)
Image: The Vivalytic MRSA/MSSA Rapid Test provides a quick diagnosis of methicillin resistance at the point of care (Photo courtesy of Randox)

Methicillin-resistant Staphylococcus aureus (MRSA) is a critical pathogen responsible for numerous hospital-acquired infections, leading to complications and increased mortality rates. The World Health Organization has estimated that patients infected with MRSA experience a mortality rate approximately 50% higher than those affected by non-resistant strains of Staphylococcus aureus. Therefore, swiftly and accurately determining whether the bacterial strain is methicillin-sensitive (MSSA) or resistant is crucial, particularly in emergency situations. Conducting MRSA/SA screening plays a significant role in mitigating health risks by curtailing contamination, breaking the chain of infection, and combating superbugs and antimicrobial resistance. Now, a rapid test provides differentiation between MRSA and MSSA in 53 minutes at the point of care.

The Vivalytic MRSA/MSSA Rapid Test from Randox Laboratories (Crumlin, UK) is a qualitative RT-PCR diagnostic test capable of identifying and distinguishing MRSA, MSSA, and methicillin-resistant coagulase-negative Staphylococci (MRCoNS). Using a single cartridge, the Vivalytic MRSA/MSSA test facilitates a speedy diagnosis of MRSA infections, allowing for the immediate application of suitable antibiotic treatment and prevention of complications. In contrast to the 1-3 days required for traditional culture sampling, the Vivalytic test provides reliable results in less than an hour right at the point of care, making it highly applicable for use in emergency departments.

The Vivalytic analyzer has been designed to be user-friendly, delivering speedy analyses and ease of handling. The patient-to-result process comprises a simple four-step procedure. The test commences when the user scans or inputs sample information and then scans the cartridge code into the integrated Vivalytic software. The sample is then added into the cartridge slot, after which the lid is closed, and the cartridge is inserted into the Vivalytic. The touchscreen display provides a countdown to the completion of the test, and results are shown on the screen. Furthermore, multiple Vivalytic devices can be wirelessly linked, enabling simultaneous control of multiple tests, all reporting to a primary Vivalytic platform.

Related Links:
Randox Laboratories 

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Coagulation Analyzer
CS-2400

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.